Updated EU GMP guide on drug quality, outsourced activities to apply from 2013
This article was originally published in SRA
Executive Summary
The European Commission has revised its good manufacturing practice guideline with updated chapters on pharmaceutical quality and outsourced activities, and an updated annex on manufacturing of biological active substances1. The revisions to the guideline will apply from January 2013.
You may also be interested in...
EU Regulators Prioritize Nitrosamine Evaluations Deadline
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
Sticking To Nitrosamine Evaluations Deadline Is Priority For EU Regulators
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
Patient Voice Makes Impact In Scientific Advice From EU HTA Network
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: